The phone goes through a bow and arrow test and gives in to this ultimate experiment of durability
4 days ago, 2:47pm CDT
The data in Apple's recently released 10-Q filing reveals the company has invested heavily in manufacturing and component purchases as it gears up for a series of highly anticipated major product launches this fall, including a next-generation iPhone and anticipated " ...
Full article at: AppleInsider
5 hours ago
Smartphones, laptops, and tablets have become essential parts of everyday life. Whether it may just be one of these that you use, or all three, the act still is that we use them every day and with their tiny nooks and crannies, they can get difficult to clean.
Jun 18 2014, 10:12am CDT
Source: Daily Mail - UK
The delay was blamed on manufacturing problems, but new reports claim the California firm doesn't want to pit the models against each other like the iPhone 5S (pictured right) ...
Full article at: Daily Mail - UK
5 hours ago
Source: Bureau of Economic Analysis
Real gross domestic product (GDP) decreased at an annual rate of 2.9 percent in the first quarter of 2014 after increasing 2.6 percent in the fourth quarter of 2013. Both private services- and goods-producing industries contributed to the decrease, while the government sector increased slightly. Durable-goods manufacturing; wholesale trade; and agriculture, forestry, fishing, and hunting were the leading contributors to the ...
Full article at: Bureau of Economic Analysis
5 hours ago
The companies have requested sapphire glass manufacturers / suppliers to review samples
May 24 2014, 1:15pm CDT
Source: The Business Insider
This chart comes from Katy Huberty of Morgan Stanley. It's based on her reading of Apple's latest quarterly filing with the SEC. She says the off-balance sheet commitments "confirm major product ramps later this year." As you can see, it would therefore also confirm Apple's revenue is going to explode. What is an "off-balance sheet commitment"? Huberty says the off-b ...
Full article at: The Business Insider
6 hours ago
Source: bidness etc
Novartis AG (ADR) (NVS) announced yesterday that the Food and Drug Administration (FDA) had accepted the Biologics License Application for filgrastim by Sandoz – the generics arm of Novartis. The acceptance is the first step towards ensuring that the drug which is similar to Amgen, Inc.’s (AMGN) Neupogen will be marketed in the US. The biosimilar version of Neupogen will serve as a cheaper alternative for cancer patients.
Neupogen is expected to generate about $1.17 billion or 6% of the ...
Full article at: bidness etc
8 hours ago
Has digital technology really made us better off? While there are lots of impressive gadgets, the impact on our...
Apr 4 2014, 11:41pm CDT